Eiger BioPharmaceuticals
PALO ALTO, California -
- Industry Veteran with Business Development and Transactional Expertise Joins Eiger Board of Directors
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies with a focus on the NS4B Hepatitis C Virus (HCV) protein, announced today the appointment of Paul Truex to its Board of Directors.
PALO ALTO, California -
- Proof of Concept Study Investigating NS4B-RNA Binding Inhibitor
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV).
PALO ALTO, California -
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University.
